Month: September 2021

Fast + Epp HeadquartersView Smart Windows installed at the new corporate headquarters for Fast + Epp in VancouverVANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — View, Inc. (NASDAQ: VIEW) (“View”), the leader in smart building technologies, today announced its Smart Windows have been installed at the new corporate headquarters for Fast + Epp, a world leader in mass-timber structural engineering and design. Fast + Epp built their new headquarters with sustainability and employee health and wellness in mind. The unique design of the new four-storey building features a hybrid mass-timber and steel structural system with cross-laminated timber floor plates, stairwells, and elevator cores. Fast + Epp included View Smart Windows to improve the building’s energy-efficiency, maximize usable floor space, and...

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021.NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced three poster presentations of new data supporting the combination of plinabulin and G-CSF for the prevention of chemotherapy-induced neutropenia (CIN) at the European Society for Medical Oncology 2021 Congress taking place virtually September 16-21, 2021. Plinabulin in combination with G-CSF is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30, 2021. The posters will become available on September 16, 2021...

– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage product candidate, SB204 for the treatment of acne vulgaris, selected to advance as second lead program toward pivotal Phase 3 study – – SB019 SARS-CoV-2 development program advancing toward Phase 1 study in healthy volunteers, targeted for 1H 2022 – – Company to host conference call and webcast today at 8:30 AM ET – DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (the “Company” or “Novan”) (Nasdaq: NOVN), today announced its key strategic priorities including its decision to advance late-stage asset, SB204, for the treatment of acne vulgaris as its second lead program. The Company provided a general update and outlined key...

Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel” or the “Company”), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual R&D Day on Thursday, September 23, 2021, from 12:00 PM – 2:00 PM ET. The event, Revolutionizing Drug Discovery and Development Through AI, will showcase the Company’s proprietary AI platform, emerging neuroscience pipeline candidates, and provide an update on expansion opportunities for the Company’s lead program, BXCL501. Vimal Mehta, Ph.D., Chief Executive Officer, and Frank Yocca,...

SÃO PAULO, Brazil, Sept. 09, 2021 (GLOBE NEWSWIRE) — XP Inc. (Nasdaq: XP), a leading, technology-driven platform and a trusted provider of low-fee financial products and services in Brazil, announced today the acquisition of a minority stake in Virgo, a financial solutions and capital markets services company. The transaction will allow Virgo to accelerate its plan to build the largest capital markets access marketplace for small and medium size companies and projects in Brazil. Virgo also intends to use the proceeds for team hiring, technology investments and the development of new products and solutions. For Pedro Mesquita, Head of Investment Banking at XP, the investment will enhance small and medium companies’ access to the capital markets. “There is a strong movement – with a significant contribution from XP Inc. – of mergers...

Lassila & Tikanoja plc Stock exchange release 9 September 2021 2.00 pm Lassila & Tikanoja’s financial information and AGM in 2022 In the year 2022 Lassila & Tikanoja plc will disclose financial information as follows: Financial statements release 2021: 27 January 2022 at 8.00 am Interim Report January – March: 27 April 2022 at 8.00 am Half-year Report January – June: 22 July 2022 at 8.00 am Interim Report January – September: 27 October 2022 at 8.00 am The Annual Report that includes the report by the Board of Directors and the financial statements for the year 2021 will be published in February in week 8. The Annual General Meeting is tentatively scheduled for Thursday 17 March 2022. The Board of Directors will decide on the summoning of the meeting at a later date. LASSILA & TIKANOJA PLC Eero Hautaniemi President...

Company announcement – No. 59/ 2021 Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2Presentations at the 2021 European Society for Clinical Nutrition and Metabolism (ESPEN) Virtual Congress include a Poster of Distinction comparing glepaglutide to short-acting GLP-2 Two additional glepaglutide posters detail PK and PD profiles following once weekly dosing in healthy subjects and subjects with varying degrees of renal functionCopenhagen, DK and Boston, MA, U.S. September 9, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced it will present...

– RWB production facility at Sanderson property built to GMP specifications – TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”), a leading provider of cannabis brands in the US, has built-out a new production facility, to GMP specifications, in order to capitalize on the growing cannabis derivative market in Florida. BDSA1 reports that, “Florida’s medical cannabis market is expected to reach $1.5 billion in sales in 2021, growing 53% over 2020.” Adding, “With both recreational and medical cannabis expected to be legal in Florida by 2023, BDSA forecasts it will grow to $2.6 billion by 2026.”                                                                                  The production facility was built within a 4,800...